Profile
ADMP ZTS HLN TAK TEVA VTRS
Company Name Adamis Pharmaceuticals Corporation Zoetis Inc. Haleon plc Takeda Pharmaceutical Company Limited Teva Pharmaceutical Industries Limited Viatris Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap $7.25M $79.26B $43.23B $42.13B $18.71B $15.67B
Employees 0.01K 14.10K 25.41K 49.28K 37.00K 32.00K
CEO Dr. Ebrahim Versi M.D., Ph.D. Ms. Kristin C. Peck Mr. Brian James McNamara Mr. Christophe Weber Mr. Richard D. Francis Mr. Scott Andrew Smith Ph.D.
Ratings
ADMP ZTS HLN TAK TEVA VTRS
Quant Rating Score 3 3 3 3 1 3
Quant Rating Neutral Neutral Neutral Neutral Strong Sell Neutral
Trading
ADMP ZTS HLN TAK TEVA VTRS
Last Close $0.775 $175.67 $9.48 $13.29 $17.03 $13.13
High 52 $0.78 $199.94 $10.69 $15.08 $18.96 $13.53
Low 52 $0.78 $145.54 $8.01 $12.6 $10.44 $10.05
Price vs. 52 Week High -0.64 % -12.14 % -11.32 % -11.87 % -10.18 % -2.96 %
Price vs. 52 Week Low -0.64 % 20.7 % 18.35 % 5.48 % 63.12 % 30.65 %
Total Return
ADMP ZTS HLN TAK TEVA VTRS
1 Month Return 0 % -7.27 % -5.01 % -6.08 % -6.33 % 13.48 %
3 Month Return 0 % -3.95 % -3.95 % -11.04 % -6.07 % 12.03 %
6 Month Return 0 % 1.67 % 11.27 % 0.68 % 2.65 % 19.8 %
9 Month Return 0 % -6.75 % 13.81 % -9.84 % 31 % -0.98 %
YTD Return 0 % -10.99 % 15.19 % -6.87 % 63.12 % 21.24 %
1 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
ADMP ZTS HLN TAK TEVA VTRS
Dividend Yield Percentage (TTM) - 0.98 % 2.08 % 4.77 % - 3.66 %
Dividend Paid and Capex Coverage Ration (TTM) - 2.1 % - 1.29 % 5.06 % 2.39 %
Dividend Per Share (TTM) - 1.73 % 0.16 % 0.63 % - 0.48 %
Payout Ratio (TTM) - 31.44 % - 101.62 % - -65.15 %
Growth
ADMP ZTS HLN TAK TEVA VTRS
Asset Growth -71.46 % -4.28 % -2.18 % 8.25 % -1.2 % -4.67 %
Gross Profit Growth 69.31 % 3.7 % 5.85 % -16.6 % 9.64 % -0.9 %
Revenue Growth 115.34 % 5.74 % 4.09 % 5.87 % 6.16 % -5.14 %
Revenue 3 Year -92.36 % 31.98 % 13.9 % 33.13 % -6.92 % -35.32 %
Revenue 5 Year -93.12 % 53.64 % 32.87 % 149.89 % -23.33 % -41.73 %
Revenue 10 Year - 103.1 % 32.87 % 154.38 % -40.82 % -26.57 %
EBIT Growth 21.86 % 6.27 % 37.26 % 7.34 % -84.52 % -52.55 %
Net Income Growth 24.28 % 10.88 % -1.04 % -54.56 % 76.24 % -97.37 %
Net Income 3 Yeari Growth Per Share 68.22 % 47.55 % -8.67 % -61.74 % 86.29 % 104.09 %
Net Income 5 Yeari Growth Per Share 80.59 % 71.94 % 59.66 % 62.27 % 76.28 % -93.3 %
Net Income 10 Yeari Growth Per Share 85.76 % 404.24 % 59.66 % 36.33 % -133.42 % -97.12 %
Operating Income Growth 21.86 % 6.27 % 37.26 % 7.34 % -84.52 % -52.55 %
Operating Cash Flow Growth (CFG) 31.45 % 23.06 % -16.48 % -34.47 % -13.96 % -5.18 %
Operating 3 Year CFG 53.7 % 14.12 % 22.08 % -36.76 % 10.09 % 13.84 %
Operating 5 Year CFG 67.62 % 37.69 % 118.54 % 139.61 % -48.98 % -48.37 %
Operating 10 Year CFG 60.43 % 274.61 % 118.54 % 335.67 % -67.94 % -16.8 %
EPS Growth 27.14 % 12.64 % - -54.92 % 76.42 % -97.08 %
EPS Diluted Growth 27.14 % 12.92 % - -54.86 % 76.42 % -97.08 %
Book Value Per Share -103 % 15.25 % 1.35 % 13.54 % -7.25 % -1.92 %
Share Holder 3 Year Equity Growth Per Share -100.8 % 36.7 % -36.6 % 40.38 % -26.74 % -55.34 %
Share Holder 5 Year Equity Growth Per Share -100.39 % 139.55 % -39.41 % 73.27 % -53.44 % -27.35 %
Share Holder 10 Year Equity Growth Per Share 99.27 % 476.36 % -39.41 % 197.1 % -74.76 % 128.81 %
Dividend Per Share Growth - 15.15 % -85.58 % 1.95 % - -0.06 %
Dividend 3 Year Growth Per Share - 87.76 % -83.69 % 1.19 % - -
Dividend 5 Year Growth Per Share - 198.29 % -66.42 % 146.94 % -100 % -
Dividend 10 Year Growth Per Share - 665.58 % -66.42 % 103.93 % -100 % -
Debt Growth -50.53 % -15.91 % -9.43 % 24.67 % -6.53 % -5.93 %
Free Cash Flow Growth 31.86 % 22.25 % -20.06 % -53.54 % -19.19 % -7.35 %
Updated On 31 Dec 2022 31 Dec 2023 31 Dec 2023 31 Mar 2024 31 Dec 2023 31 Dec 2023
Profitability
ADMP ZTS HLN TAK TEVA VTRS
Gross Profit Margin TTM 96.02 % 68.87 % 59.91 % 62.47 % 49.87 % 40.26 %
Return on Assets TTM -0.09 % 16.93 % 3.26 % 1.99 % -2.38 % -1.97 %
Return on Equity TTM 0.33 % 47.99 % 6.54 % 4.04 % -14.58 % -4.43 %
Return on Capital Employed TTM 0.32 % 26.64 % 7.25 % 5.27 % 7.66 % -0.71 %
Net Income Per EBT TTM 123.6 % 79.65 % 65.38 % 109.03 % 175.89 % 92.81 %
EBT Per Ebit TTM 45.68 % 90.51 % 82.66 % 41.38 % -26.34 % 359.67 %
EBIT Per Revenue TTM -160.65 % 36.83 % 17.88 % 14.14 % 12.76 % -1.76 %
Cash Flow To Debt Ratio TTM -4.06 % 44.8 % - 17.01 % 13 % 13.05 %
Receivables Turnover TTM - 6.49 5.27 6.3 4.85 3.81
Payables Turnover TTM - 7.05 1.25 4.13 3.55 7.23
Inventory Turnover TTM - 1.18 3.09 1.41 2.13 2.2
Fixed Asset Turnover TTM 0.84 % 259.93 % 604.62 % 240.84 % 278.05 % 561.67 %
Asset Turnover TTM 0.1 % 63.75 % 33.71 % 31.2 % 40.19 % 33.6 %
Operating Cash Flow Per Share TTM -0.36 6.5 - 545.34 2.18 1.93
Free Cash Flow Per Share TTM -0.36 5.1 - 309.43 1.75 1.6
Cash Per Share TTM 94314.03 % 378.45 % 5.72 % 57513.46 % 292.94 % 157.41 %
Operating Cash Flow Sales Ratio TTM -28.32 % 32.18 % - 18.9 % 14.71 % 15.29 %
Free Cash Flow Operating Cash Flow Ratio TTM 100 % 78.37 % - 56.74 % 80.23 % 83.19 %
Cash Flow Coverage Ratios TTM -4.06 % 44.8 % - 17.01 % 13 % 13.05 %
Price To Free Cash Flows Ratio TTM -2.82 34.34 - 13.34 9.45 8.19
Price To Operating Cash Flows Ratio TTM -2.13 27.02 - 3.76 7.82 6.81
Price Cash Flow Ratio TTM -2.13 27.02 - 3.76 7.82 6.81
Income Statement (TTM)
ADMP ZTS HLN TAK TEVA VTRS
Revenue $0B $8.54B $11.3B $4263.76B $15.85B $15.43B
Gross Profit $-0B $5.83B $6.96B $2321.31B $7.65B $6.44B
Gross Profit Ratio -30.1% 68.28% 61.6% 54.44% 48.25% 41.74%
EBITDA $-0.02B $3.69B $2.35B $900.33B $4.33B $3.52B
Net Income $-0.03B $2.34B $1.05B $144.07B $-0.56B $0.05B
EPS Diluted -12.24 5.07 0.11 91.16 -0.5 0.05
Balance Sheet (MRQ)
ADMP ZTS HLN TAK TEVA VTRS
Long Term Debt $0B $6.75B $8.95B $5029.93B $18.48B $16.35B
Total Liabilities $0.01B $9.3B $17.33B $7834.79B $35.35B $27.22B
Total Equity $-0B $4.99B $16.73B $7274.01B $8.13B $20.47B
Total Investments $0B $0.02B $0.07B $683.22B $0.01B $1.33B
Total Debt $0B $6.76B $9.46B $5463.39B $20.15B $18.37B
Total Assets $0.01B $14.29B $34.06B $15108.79B $43.48B $47.69B
Cash Flow Statement (TTM)
ADMP ZTS HLN TAK TEVA VTRS
Net Income $-0.03B $2.34B $1.05B $144.07B $-0.62B $0.05B
Inventory $-0B $-0.36B $-0.13B $-115.74B $0B $-0.61B
Dividends Paid $0B $-0.69B $-0.39B $-287.19B $0B $-0.58B
Operating Cash Flow $-0.03B $2.35B $1.72B $640.32B $1.37B $2.8B
Capital Expenditure $-0B $-0.73B $-0.34B $-480.73B $-0.53B $-0.47B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 4.32
ACOR Acorda Therapeutics, Inc. 0.661
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMS Adamas Pharmaceuticals, Inc. 8.22
AERI Aerie Pharmaceuticals, Inc. 15.25
AGRX Agile Therapeutics, Inc. 1.51
AKAN Akanda Corp. 1.33
ALIM Alimera Sciences, Inc. 5.54
ALVO Alvotech 12.33
ALVOW Alvotech 3.49
AMPH Amphastar Pharmaceuticals, Inc. 44.58
AMRX Amneal Pharmaceuticals, Inc. 8.33
AMYT Amryt Pharma plc 14.7
ANIP ANI Pharmaceuticals, Inc. 56.315
AQST Aquestive Therapeutics, Inc. 4.585
ASRT Assertio Holdings, Inc. 0.9467
ATNX Athenex, Inc. 0.2031
AVDL Avadel Pharmaceuticals plc 11.5
AYTU Aytu BioPharma, Inc. 1.471
BDSI BioDelivery Sciences International, Inc. 5.59
ETFs With Exposure to ADMP
Ticker ETF Name Weight Percentage Price
VTI Vanguard Total Stock Market Index Fund 0 295.529
ITOT iShares Core S&P Total U.S. Stock Market ETF 0 131.23
Unlock